AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35544287 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 309
Study 35544287 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 309
Study 35544727 — intervention group
Group type: EXPERIMENTAL
Intervention: First- or second-line systemic therapy for advanced/metastatic CCA
Number of subjects: 0
Study 35544727 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35544759 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine (40 mL)
Number of subjects: 15
Study 35544759 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chloroprocaine (40 mL)
Number of subjects: 15
Study 35544759 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine (40 mL)
Number of subjects: 15
Study 35544759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chloroprocaine
Number of subjects: 15
Study 35545011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-S100A8/A9 antibody
Number of subjects: 0
Study 35545011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 0
Study 35545011 — intervention group
Group type: EXPERIMENTAL
Intervention: Flo1-2a anti-murine anti-IL-1α monoclonal antibody
Number of subjects: 0
Study 35545011 — intervention group
Group type: COMPARATOR
Intervention: XB2001 (specific anti-human IL-1α antibody)
Number of subjects: 0
Study 35545011 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 35545392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) assessment of atrial fibrosis in the left atrium (LA) at baseline
Number of subjects: 100
Study 35545392 — intervention group
Group type: COMPARATOR
Intervention: Control group without established cardiovascular disease
Number of subjects: 100
Study 35545433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Capture 2 High-Risk test (HC2)
Number of subjects: 274
Study 35545433 — intervention group
Group type: EXPERIMENTAL
Intervention: LINEAR ARRAY HPV Genotyping Test (LA)
Number of subjects: 274
Study 35545433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methodologies (HC2 and LA)
Number of subjects: 274
Study 35545433 — intervention group
Group type: EXPERIMENTAL
Intervention: Total HPV detection (HC2)
Number of subjects: 274
Study 35545433 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-specific HPV16/18 genotyping (LA)
Number of subjects: 274
Study 35545433 — intervention group
Group type: EXPERIMENTAL
Intervention: Total HPV detection or type-specific HPV16/18 detection with a threshold ≥ atypical squamous cells of undetermined significance for abnormal cytology
Number of subjects: 274
Study 35545657 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed lifestyle treatment using a digital tool
Number of subjects: 370
Study 35545778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat alone or in combination with azacitidine
Number of subjects: 23
Study 35545778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat plus azacitidine
Number of subjects: 23
Study 35545778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Number of subjects: 23
Study 35545947 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel multianalyte assay
Number of subjects: 1036
Study 35545947 — intervention group
Group type: COMPARATOR
Intervention: Negative assay result
Number of subjects: 1036
Study 35546043 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg) for 8 weeks
Number of subjects: 208
Study 35546145 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) 200-300mL with a predefined minimum level of antibodies
Number of subjects: 797
Study 35546145 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP)
Number of subjects: 797
Study 35546145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study 35546205 — intervention group
Group type: COMPARATOR
Intervention: Chronic HCV infection in patients with APAP overdose
Number of subjects: 2999
Study 35546205 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hepatitis C infection
Number of subjects: 2999
Study 35546205 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV seroconversion
Number of subjects: 2999
Study 35546205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation due to ALF
Number of subjects: 2999
Study 35546228 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention
Number of subjects: 18
Study 35546275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist
Number of subjects: 10675
Study 35546275 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylureas, thiazolidinediones, meglitinides or insulin
Number of subjects: 10675
Study 35546396 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and stabilization occlusal splint
Number of subjects: 35
Study 35546401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronolis®HD mono 2.5% (high-density sterile viscoelastic solution of hyaluronic acid)
Number of subjects: 166
Study 35546401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronolis®HD mono 2.5%
Number of subjects: 166
Study 35546402 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxysalicylanilide (HDS)
Number of subjects: 0
Study 35546402 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxysalicylanilide (HDS) in combination with melphalan and bortezomib
Number of subjects: 0
Study 35546414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron ODT 0.1 mg administered after discharge on postoperative days 1 and 2
Number of subjects: 138
Study 35546414 — intervention group
Group type: COMPARATOR
Intervention: Control group (metoclopramide 10 mg administered only when nausea/vomiting occurred)
Number of subjects: 138
Study 35546525 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35546555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100-300 mg administered intravenously for 15 days)
Number of subjects: 0
Study 35546555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 35546555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in the context of ongoing Phase IIB trial)
Number of subjects: 0
Study 35546638 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty (PKP)
Number of subjects: 316
Study 35546669 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² initial dose)
Number of subjects: 256
Study 35546669 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 256
Study 35546672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide
Number of subjects: 5
Study 35546790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 3.0 mg
Number of subjects: 2958
Study 35546790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 4.5 mg
Number of subjects: 2958
Study 35546790 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 2958
Study 35546953 — intervention group
Group type: EXPERIMENTAL
Intervention: My Grief app for 4 weeks
Number of subjects: 13
Study 35547849 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg of mRNA-1273
Number of subjects: 0
Study 35547849 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mcg of mRNA-1273.351
Number of subjects: 0
Study 35547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent vaccine of 25 mcg each of mRNA-1273 and mRNA-1273.351
Number of subjects: 0
Study 35547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Third mRNA vaccination
Number of subjects: 0
Study 35547857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain training for respite workers (3-3.5 hours duration)
Number of subjects: 0
Study 35548056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724
Study 35548056 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 724
Study 35548075 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital exercise programme (Safe Step) with optional supportive strategies
Number of subjects: 0
Study 35548075 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital fall prevention intervention
Number of subjects: 0
Study 35548436 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological control mode
Number of subjects: 6
Study 35548439 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 90
Study 35548446 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced bolus bivalirudin (80% of normal dose)
Number of subjects: 204
Study 35548446 — intervention group
Group type: COMPARATOR
Intervention: Normal bolus bivalirudin
Number of subjects: 204
Study 35548446 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative net adverse clinical events (NACEs)
Number of subjects: 204
Study 35548564 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian-based oil blends rich in unsaturated fats (refined rice bran, sesame, and flaxseed oils)
Number of subjects: 66
Study 35548564 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil
Number of subjects: 66
Study 35548581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Exercise Program (DEP)
Number of subjects: 90
Study 35548581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 90
Study 35548581 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 35549377 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization (Thrombolysis in Cerebral Infarction scale score ≥2b)
Number of subjects: 3057
Study 35549377 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS at 24 hours
Number of subjects: 3057
Study 35549377 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS at hospital discharge
Number of subjects: 3057
Study 35549640 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35549674 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab in combination with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 67
Study 35549674 — intervention group
Group type: COMPARATOR
Intervention: FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 67
Study 35549733 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) control using the ARG algorithm
Number of subjects: 5
Study 35549733 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (OL) control
Number of subjects: 5
Study 35549810 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd)
Number of subjects: 0
Study 35549810 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35549838 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 35549838 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35550037 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines (various Emergency Use Authorization or licensed formulations)
Number of subjects: 265
Study 35550158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body temperature (Tb)
Number of subjects: 0
Study 35550158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body temperature (Tb) during waking
Number of subjects: 0
Study 35550158 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and CSF P-tau levels
Number of subjects: 0
Study 35550708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment (HT)
Number of subjects: 32
Study 35550847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial
Number of subjects: 0
Study 35551049 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic period
Number of subjects: 166459
Study 35551072 — intervention group
Group type: EXPERIMENTAL
Intervention: Surpass flow diverter treatment
Number of subjects: 38
Study 35551077 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain radiating to both arms
Number of subjects: 1506
Study 35551077 — intervention group
Group type: EXPERIMENTAL
Intervention: Exertional chest pain during the last week
Number of subjects: 1506
Study 35551077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during activity
Number of subjects: 1506
Study 35551077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain dependent on position, respiration or palpation (Men)
Number of subjects: 1506
Study 35551077 — intervention group
Group type: EXPERIMENTAL
Intervention: Exertional chest pain during the last week (<70 years)
Number of subjects: 1506
Study 35551077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain radiating to the left arm (<70 years)
Number of subjects: 1506
Study 35551083 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised Dynamic Posturography (Equitest, NeuroCom, Clackamas, OR)
Number of subjects: 45
Study 35551083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative posturographic results
Number of subjects: 45
Study 35551087 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) on days 5-7, in addition to standard of care radiotherapy and immunotherapy.
Number of subjects: 60
Study 35551087 — intervention group
Group type: COMPARATOR
Intervention: Standard of care radiotherapy and immunotherapy.
Number of subjects: 60
Study 35551122 — intervention group
Group type: EXPERIMENTAL
Intervention: ER2 recommendations in addition to usual ED care
Number of subjects: 356
Study 35551122 — intervention group
Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 356
Study 35551148 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 14
Study 35551148 — intervention group
Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 14
Study 35551148 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Macintosh to Airtraq
Number of subjects: 14
Study 35551157 — intervention group
Group type: EXPERIMENTAL
Intervention: Work2Prevent intervention (4-session employment and HIV prevention intervention)
Number of subjects: 87
Study 35551366 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccines (mRNA-1273, BNT162b2)
Number of subjects: 375
Study 35551444 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery
Number of subjects: 0
Study 35551488 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of Parkin
Number of subjects: 0
Study 35551488 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of ATG5
Number of subjects: 0
Study 35551610 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 24
Study 35551866 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation for pain
Number of subjects: 88
Study 35551868 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation-naïve patients
Number of subjects: 263
Study 35551868 — intervention group
Group type: COMPARATOR
Intervention: Patients with previous SCS experience
Number of subjects: 263
Study 35551868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 263
Study 35552391 — intervention group
Group type: EXPERIMENTAL
Intervention: FET-PET-based SIB intensity-modulated radiotherapy (78 Gy total dose, 2.6 Gy per fraction)
Number of subjects: 17
Study 35552391 — intervention group
Group type: EXPERIMENTAL
Intervention: FET-PET-based SIB intensity-modulated radiotherapy
Number of subjects: 17
Study 35552447 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib, Hydroxychloroquine (HCQ), and Entinostat
Number of subjects: 20
Study 35552504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular outpatient care visits in 2020
Number of subjects: 0
Study 35552504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular hospitalizations in 2020
Number of subjects: 0
Study 35552504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality in 2020
Number of subjects: 0
Study 35552504 — intervention group
Group type: EXPERIMENTAL
Intervention: Home deaths due to cardiovascular issues in 2020
Number of subjects: 0
Study 35552677 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (PTX)
Number of subjects: 0
Study 35552677 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of SSR3
Number of subjects: 0
Study 35552677 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockout (KO) of SSR3
Number of subjects: 0
Study 35552677 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR knockout (KO) screen
Number of subjects: 0
Study 35552677 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with survival in breast cancer patient cohorts treated with PTX
Number of subjects: 0
Study 35552827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (fixed dose, 10,000 Anti-Xa IU, OD)
Number of subjects: 291
Study 35553047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1600 mg
Number of subjects: 634
Study 35553047 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 300 mg
Number of subjects: 634
Study 35553047 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg
Number of subjects: 634
Study 35553047 — intervention group
Group type: COMPARATOR
Intervention: Ambulation during treatment
Number of subjects: 634
Study 35553047 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ibuprofen 800 mg
Number of subjects: 634
Study 35553047 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 2000 mg
Number of subjects: 634
Study 35553047 — intervention group
Group type: COMPARATOR
Intervention: Ambulation or non-ambulation
Number of subjects: 634
Study 35553414 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 54
Study 35553414 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 54
Study 35554583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild sleep-disordered breathing
Number of subjects: 912
Study 35554583 — intervention group
Group type: COMPARATOR
Intervention: Obstructive sleep apnea
Number of subjects: 912
Study 35554589 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT HSAT
Number of subjects: 167
Study 35554589 — intervention group
Group type: COMPARATOR
Intervention: PSG
Number of subjects: 167
Study 35554653 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI dedicated to the ED (after period)
Number of subjects: 380
Study 35554653 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic workup without MRI (before period)
Number of subjects: 380
Study 35554653 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI dedicated to the ED
Number of subjects: 380
Study 35554877 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted difficulty scoring system (CAD)
Number of subjects: 173
Study 35557615 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (GC) exposure during pregnancy
Number of subjects: 80
Study 35557615 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 80
Study 35558645 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid prescriptions at discharge
Number of subjects: 1345
Study 35558645 — intervention group
Group type: COMPARATOR
Intervention: Trauma center volume
Number of subjects: 1345
Study 35558645 — intervention group
Group type: COMPARATOR
Intervention: Alcohol and other drugs (AOD) status
Number of subjects: 1345
Study 35559350 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF23
Number of subjects: 62
Study 35559350 — intervention group
Group type: COMPARATOR
Intervention: RAAS parameters (PRA-S, AngII, aldosterone)
Number of subjects: 62
Study 35559387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis combined with mechanical thrombectomy (Group A)
Number of subjects: 120
Study 35559387 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment and intravenous thrombolysis (Group B)
Number of subjects: 120
Study 35559998 — intervention group
Group type: COMPARATOR
Intervention: sCD146 and Gal1 concentrations in women with normal pregnancies
Number of subjects: 115
Study 35559998 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD146 concentrations in women with preeclampsia
Number of subjects: 115
Study 35559998 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophoblast migration
Number of subjects: 115
Study 35559998 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD146 as a biomarker
Number of subjects: 115
Study 35560143 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping with genome-wide SNP-arrays
Number of subjects: 1100
Study 35560143 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycome profiling
Number of subjects: 1100
Study 35560143 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing
Number of subjects: 1100
Study 35560860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic children
Number of subjects: 900
Study 35560860 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black (NHB) children
Number of subjects: 900
Study 35560860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic and Non-Hispanic White (NHW) children
Number of subjects: 900
Study 35560860 — intervention group
Group type: COMPARATOR
Intervention: MetS definitions
Number of subjects: 900
Study 35560860 — intervention group
Group type: EXPERIMENTAL
Intervention: MetS prevalence
Number of subjects: 900
Study 35561317 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term breast cancer survivors (10-15 years post-diagnosis)
Number of subjects: 6641
Study 35561317 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer survivors with Charlson Comorbidity Index score ≥2
Number of subjects: 6641
Study 35561317 — intervention group
Group type: COMPARATOR
Intervention: General population (cancer-free women matched by birth year and state)
Number of subjects: 6641
Study 35561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional HCC (cHCC)
Number of subjects: 262
Study 35561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated α-fetoprotein
Number of subjects: 262
Study 35561331 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocality
Number of subjects: 262
Study 35561331 — intervention group
Group type: EXPERIMENTAL
Intervention: PRETEXT stage IV
Number of subjects: 262
Study 35561331 — intervention group
Group type: EXPERIMENTAL
Intervention: cHCC vs FLC
Number of subjects: 262